European Journal of Immunogenetics (1995), **22**, 487–490

AUTHOR INDEX

AKAZA, T. *see* MITSUNAGA, S.
ALBERT, E. *see* BODMER, J. G.; EPPLEN, C.
ALEXOUPOLOS, S. *see* VAUGHAN, R. W.
ALLEN, M. *see* CIUSANI, E.
ANDERSEN, H. H. *see* CHRISTIANSEN, O. B.
AL-ARBASH, M. *see* AL-FOUZAN, A.
AUSSEL, L. *see* DROUET, M.
AWOMOYI, A. A. O., DONN, R. P., DAVIES, E. J., CARTHY, D., THOMSON, W., OLLIER, W. E. R. Absence of TAP 2D in Yoruba Nigerians 187-190

BADENHOOP, K. *see* RAU, H.
BAOUZ, A. *see* HORS, J.
BAROUCH, D. *see* KRAUSA, P.
BIDWELL, J. L. *see* CLAY, T. M.
BLASCZYK, R. *see* LORENZ, A.
BODMER, J. G., MARSH, S. G. E., ALBERT, E. D., BODMER, W. F., BONTROP, R. E., CHARRON, D., DUPONT, B., ERLICH, H. A., MACH, B., MAYR, W. R., PARHAM, P., SASAZUKI, T., SCHREUDER, G. M. TH., STROMINGER, J. L., SVEJGAARD, A., TERASAKI, P. I. Nomenclature for factors of the HLA system 1995 335-60
BODMER, J. G. *see also* KRAUSA, P.
BODMER, W. F. *see* BODMER, J. G.
BOKI, K. *see* VAUGHAN, R. W.
BONTROP, R. E. *see* BODMER, J. G.
BOROS, P. *see* PETRÁNYI, G.
BOYLE, A. J. *see* VARNEY, M. D.
BRADLEY, B. A. *see* CLAY, T. M.
BROWNING, M. J. *see* KRAUSA, P.
BUC, M. *see* DEMOŠOVÁ, V.
BUSSON, M. *see* HORS, J.

CABRERA, T. *see* CONCHA, A.
CARTHY, D. *see* AWOMOYI, A. A. O.
CHARRON, D. *see* BODMER, J. G.; LEPAGE, V.
CHRISTIANSEN, O. B., ANDERSEN, H. H., HØJBJERRE, M., KRUSE, T. A., LAURITZEN, S. L., GRUNNET, N. Maternal HLA class II allogenotypes are markers for the predisposition to fetal losses in families of women with unexplained recurrent fetal loss 323-4
CIUSANI, E., ALLEN, M., SANDBERG-WOLLHEIM, M., EOLI, M., SALMAGGI, A., MILANESE, C., NESPOLO, A., GYLLENSTEN, U. Analysis of HLA class II DQA1, DQB1, DRB1 and DPB1 in Italian multiple sclerosis patients 171-178
CLAY, T. M., CULPAN, D., PURSALL, M. C., BRADLEY, B. A., BIDWELL, J. L. *HLA-DQB1* and *DOA1* matching by ambient temperature PCR-SSCP 467-78
COLLADO, A. *see* CONCHA, A.
CONCHA, A., RUIZ-CABELLO, F., CABRERA, T., NOGALES, F., COLLADO, A., GARRIDO, F. Different patterns of HLA-DR antigen expression in normal epithelium, hyperplastic and neoplastic malignant lesions of the breast 299-310
CULPAN, D. *see* CLAY, T. M.

DAHLQUIST, G. *see* KOCKUM, I.
DARKE, C. *see* YOUNG, N. T.
DAVIES, E. J. *see* AWOMOYI, A. A. O.
DAWKINS, R. L. *see* NITYANAND, S.
DE PABLO, R. *see* VILCHES, C.
DELFINO, L. *see* FIORE, M.
DEMOŠOVÁ, V., BUC, M., FERENČÍK, S., SASAZUKI, T., SHAWKATOVÁ, I., PORUBSKÁ, S. The role of HLA class II antigens in the induction of cytotoxic lymphocytes 425-34
DEWAR, K. *see* YOUNG, N. T.
DONN, R. P. *see* AWOMOYI, A. A. O.
DOUAY, C. *see* LEPAGE, V.
DRENOU, B. *see* DROUET, M.
DROUET, M., AUSSEL, L., DRENOU, B., FAUCHET, R. Quantification and molecular analysis of plasmatic HLA-BCw molecules with a locus B and Cw HLA specific mAb (B1·23·2 mAb) 363-70
DRUMMOND, B. P. *see* TAIT, B. D.
DUPONT, B. *see* BODMER, J. G.

EASTMAN, S. *see* KOCKUM, I.
ELLIS, S. A., MARTIN, A. J., HOLMES, E. C., MORRISON, W. I. At least four MHC class I genes are transcribed in the horse: phylogenetic analysis suggests an unusual evolutionary history for the MHC in this species 249-60
EOLI, M. *see* CIUSANI, E.

EPPLEN, C., RUMPF, H., ALBERT, E., HAAS, P., TRUCKENBRODT, H., EPPLEN, J. T. Immunoprinting excludes many potential susceptibility genes as predisposing to early onset pauciarticular juvenile chronic arthritis except *HLA* class II and *TNF* 311-22
EPPLEN, J. T. *see* EPPLEN, C.
ERLICH, H. A. *see* BODMER, J. G.

FAUCHET, R. *see* DROUET, M.
FERENČÍK, S. *see* DEMOŠOVÁ, V.
FERRARA, G. B. *see* FIORE, M.
FIORE, M., PERA, C., DELFINO, L., SCOTESE, I., FERRARA, G. B., PIGNATA, C. DNA typing of DQ and DR alleles in IgA-deficient subjects 403-11
FOUAD, F. *see* AL-FOUZAN, A.
AL-FOUZAN, A., AL-ARBASH, M., FOUAD, F., KAABA, S. A., MOUSA, M. A., AL-HARIB, S. A. Study of HLA class I/II and T lymphocyte subsets in Kuwaiti vitiligo patients 209-13
FUJII, H.*see* KUWABARA, N.
FUKUTOMI, O. *see* KUWABARA, N.
FÜLÖP, V. *see* PETRÁNYI, G.

GARRIDO, F. *see* CONCHA, A.
GIBSON, K. *see* YOUNG, N. T.
GILL III, T. J. *see* SALGAR, S. K.
GRAUGAARD, B. *see* HOFFMANN, H. J.
GROSSE-WILDE, H. *see* KUBENS, B. S.; LORENZ, A.
GRUNNET, N. *see* CHRISTIANSEN, O. B.
GYLLENSTEN, U. *see* CIUSANI, E.
GYÓDI, É. *see* PETRÁNYI, G.

HAAS, P. *see* EPPLEN, C.
HAŁASA, J. *see* KACPRZAK-BERGMAN, I.
AL-HARIB, S. A. *see* AL-FOUZAN, A.
HARRISON, L. C. *see* TAIT, B. D.
HERRERO, M. J. *see* VILCHES, C.
HOFFMANN, H. J., KRISTENSEN, T. J., JENSEN, T. G., GRAUGAARD, B., LAMM, L. U. Antigenic characteristics and cDNA sequences of HLA-B73 231-40
HOLM, G. *see* NITYANAND, S.
HOLMES, E. C. *see* ELLIS, S. A.
HORS, J., BUSSON, M., RAFFOUX, C., BAOUZ, A., WESER, A. 'Bio-id': restricted use of HLA markers to detect double registration on computer files 221-23
HØJBJERRE, M. *see* CHRISTIANSEN, O. B.

ILLÉS, P. *see* PETRÁNYI, G.
IVANOVA, R. *see* LEPAGE, V.

JENSEN, T. G. *see* HOFFMANN, H. J.
JUJI, T. *see* MITSUNAGA, S.

KAABA, S. A. *see* AL-FOUZAN, A.
KACPRZAK-BERGMAN, I., HAŁASA, J. Frequency of Gm and Km phenotypes in children with mumps meningitis 393-6
KASAHARA, K. *see* OZAWA, T.
KASSAI, M. *see* PETRÁNYI, G.
KOCKUM, I., SANJEEVI, C. B., EASTMAN, S., LANDIN-OLSSON, M., DAHLQUIST, G., LERNMARK, Å. Population analysis of protection by HLA-DR and DQ genes from insulin-dependent diabetes mellitus in Swedish children with insulin-dependent diabetes and controls 443-65
KOMORI, T., SUGIYAMA, H. Deletion of the 3' splice site of the leader-variable region intron of immunoglobulin heavy chain genes induces a direct splicing of leader to constant region, resulting in the production of truncated m-chains 241-7
KONDO, N. *see* KUWABARA, N.; OZAWA, T.
KRAUSA, P., BAROUCH, D., BODMER, J. G., BROWNING, M. J. Rapid characterization of HLA class I allele by gene mapping using ARMS PCR 283-7
KREISLER, M. *see* VILCHES, C.
KRISTENSEN, T. J. *see* HOFFMANN, H. J.
KRUMBACHER, K. *see* KUBENS, B. S.
KRUSE, T. A. *see* CHRISTIANSEN, O. B.
KUBENS, B. S., KRUMBACHER, K., GROSSE-WILDE, H. Biochemical defnimition of DLA-A and DLA-B gene products by one-dimensional isoelectric focusing and immunoblotting 199-207
KUHN, U. *see* LORENZ, A.
KUNZ, H. W. *see* SALGAR, S. K.
KUWABARA, N., KONDO, N., FUKUTOMI, O., FUJII, H., ORII, T. Methylation patterns of Iε region in B cells stimulated with interleukin 4 and Epstein-Barr virus in patients with a high level of serum IgE 265-75

LAMM, L. U. *see* HOFFMANN, H. J.
LANCHBURY, J. S. S. *see* VAUGHAN, R. W.
LANDIN-OLSSON, M. *see* KOCKUM, I.
LAURITZEN, S. L. *see* CHRISTIANSEN, O. B.
LEFVERT, A. K. *see* NITYANAND, S.
LEPAGE, V., IVANOVA, R., LOSTE, M. N., MALLET, C., DOUAY, C., NAUOMOVA, E., CHARRON, D. Determination of DQB1 alleles using PCR amplification and allele-specific primers 412-22
LERNMARK, Å. *see* KOCKUM, I.
LITHELL, H. *see* NITYANAND, S.

LORENZ, A., BLASCZYK, R., KUHN, U., VENJAKOB, M., MENDONCA, M., GROSSE-WILDE, H. Strong association between the responder status of the FCγII receptor and recurrent spontaneous abortion 397-401
LOSTE, M. N. *see* LEPAGE, V.

MACH, B. *see* BODMER, J. G.
MALLET, C. *see* LEPAGE, V.
MARSH, S. G. E. Nomenclature for factors of the HLA system, update June 1995 361-2; July 1995 423-4; August 1995 485-6
MARSH, S. G. E. *see* ALSO BODMER, J. G.
MARTÍN, A. J. *see* ELLIS, S. A.
MARTIN, R. *see* VILCHES, C.
MAYR, W. R. *see* BODMER, J. G.
MENDONCA, M. *see* LORENZ, A.
MILANESE, C. *see* CIUSANI, E.
MITSUNAGA, S., OGUCHI, T., MORIYAMA, S., TOKUNAGA, K., AKAZA, T., TADOKORO, K., JUJI, T. Multiplex ARMS-PCR-RFLP method for high-resolution typing of HLA-DRB1 371-92
MORENO, M. E. *see* VILCHES, C.
MORIYAMA, S. *see* MITSUNAGA, S.
MORRISON, W. I. *see* ELLIS, S. A.
MOTOYOSHI, F. *see* OZAWA, T.
MOUSA, M. A. *see* AL-FOUZAN, A.

NAUOMOVA, E. *see* LEPAGE, V.
NESPOLO, A. *see* CIUSANI, E.
NITYANAND, S., DAWKINS, R. L., LITHELL, H., HOLM, G., LEFVERT, A. K. C4 null alleles in a Swedish population 435-41
NOGALES, F. *see* CONCHA, A.

OGUCHI, T. *see* MITSUNAGA, S.
OLLIER, W. E. R. *see* AWOMOYI, A. A. O.
OMMERT, S. *see* RAU, H.
ORII, T. *see* KUWABARA, N.; OZAWA, T.
OZAWA, T., KONDO, N., MOTOYOSHI, F., KASAHARA, K., ORII, T. DNA mutation induced in the sequence upstream of the secreted MYU C-terminal coding sequence by ultraviolet irradiation in the cell line of Bloom's syndrome 163-9

DE PABLO, R. *see* VILCHES, C.
PÁDANYI, Á. *see* PETRÁNYI, G.
PAPADAKIS, J. *see* VAUGHAN, R. W.
PARHAM, P. *see* BODMER, J. G.
PERA, C. *see* FIORE, M.
PETRÁNYI, G., PADÁNYI, Á., SZELÉNYI, J., SÁRMAY, G., GYÓDI, É., FÜLÖP, V., KASSAI, M., ILLÉS, P., RÉTI, M., SZIGETVÁRI, I, BOROS, P. The polymorphic human TLX-B/CD46/MCP system and its implications in transplantation and reproduction 147-61
PIGNATA, C. *see* FIORE, M.
PORUBSKÁ, S. *see* DEMOŠOVÁ, V.
PURSALL, M. C. *see* CLAY, T. M.

RAFFOUX, C. *see* HORS, J.
RAU, H., USADEL, K. H., OMMERT, S., BADENHOOP, K. PVU II polymorphism of LST-1 (leucocyte specific transcript 1) in type I diabetes mellitus, Graves' disease and healthy controls 277-82
RÉTI, M. *see* PETRÁNYI, G.
RUIZ-CABELLO, F. *see* CONCHA, A.
RUMPF, H. *see* EPPLEN, C.

SALGAR, S. K., KUNZ, H. W., GILL III, T. J. Expression of the rat MHC class I gene in the humand B lymphoblastoid cell line Hmy 2CIR2CIR 479-83
SALMAGGI, A. *see* CIUSANI, E.
SANDBERG-WOLLHEIM, M. *see* CIUSANI, E.
SANJEEVI, C. B. *see* KOCKUM, I.
SÁRMAY, G. *see* PETRÁNYI, G.
SASAZUKI, T. *see* BODMER, J. G.; DEMOŠOVÁ, V.
SCHREUDER, G. M. TH. *see* BODMER, J. G.
SCOTESE, I. *see* FIORE, M.
SHAWKATOVÁ, I. *see* DEMOŠOVÁ, V.
SOLÍS, R. *see* VILCHES, C.
STROMINGER, J. L. *see* BODMER, J. G.
SUGIYAMA, H. *see* KOMORI, T.
SVEJGAARD, A. *see* BODMER, J. G.
SZELÉNYI, J. *see* PETRÁNYI, G.
SZIGETVÁRI, I *see* PETRÁNYI, G.

TADOKORO, K. *see* MITSUNAGA, S.
TAIT, B. D., DRUMMOND, B. P., VARNEY, M. D., HARRISON, L. C. HLA-DRB1*0401 is associated with susceptibility to insulin-dependent diabetes mellitus independently of the DQB1 locus 289-97
TAIT, B. D. *see* VARNEY, M. D.
TERASAKI, P. I. *see* BODMER, J. G.
THOMPSON, J. *see* YOUNG, N. T.
THOMSON, W. *see* AWOMOYI, A. A. O.
TIGHE, M. R. *see* VAUGHAN, R. W.
TOKUNAGA, K. *see* MITSUNAGA, S.
TRUCKENBRODT, H. *see* EPPLEN, C.

USADEL, K. H. *see* RAU, H.

VARNEY, M. D., BOYLE, A. J., TAIT, B. D. Molecular typing and haplotypic associations of HLA-B*44 subtypes 215-20
VARNEY, M. D. *see* TAIT, B. D.
VAUGHAN, R. W., TIGHE, M. R., BOKI, K., ALEXOUPOLOS, S., PAPADAKIS, J., LANCHBURY, J. S. S., WELSH, K. I., WILLIAMS, D. G. An analysis of HLA class II gene polymorphism in British and Greek idiopathic membranous nephropathy patients 179-186
VENJAKOB, M. *see* LORENZ, A.
VILCHES, C., DE PABLO, R., SOLÍS, R., MARTÍN, R., HERRERO, M. J., MORENO, M. E., KREISLER, M. A novel TaqI/DQA RFLP associated with HLA-DR9, DQ9 (DQA1*0302) 261-4
WELSH, K. I. *see* VAUGHAN, R. W.
WESER, A. *see* HORS, J.
WILLIAMS, D. G. *see* VAUGHAN, R. W.
YOUNG, N. T., THOMPSON, J., GIBSON, K., DEWAR, K., DARKE, C. Immunogentic analysis of HLA-DR10 homozygous individuals 191-7

European Journal of Immunogenetics (1994), **21,** 491–495

SUBJECT INDEX

abortion, spontaneous (RSA)
  FCγII receptor responder status 397-401
  FctR blocking antibody production 147-61
  HLA class II allogenotype markers 323-34
  human genetic markers 323-34
allele names, deleted, WHO policy 335-60
allele naming, WHO policy 335-60
allele-specific amplification *see* PCR-ASA
alloantibodies, to TLX antigens 147-61
antigen, CD46 147-61
antigenic characteristics, HLA-B73 231-40
antisera, B73 231-40
ARMS-PCR
  class I gene characterization 283-7
  for TAP allele frequencies 187-90
  and TAP 1 allele assignment difficulty 187-90
  see also multiplex ARMS-PCR
autoantibodies, IgA-D, and DR4/DR13 403-11
autoimmune disease, allele predisposition 277-82; *see also specific disease*

B cells
  IgE production 265-75
  truncated m-chain production 241-7
b2-microglobulin — class I heavy chain heterodimerism 479-83
Bio-ID 221-3
Bloom's syndrome: *see* BS
bone marrow transplantation
  DQB1 and DQA1 matching 467-78
  HLA-DP/DQ role 425-34
breast lesions, HLA-DR expression 299-310
BS (Bloom's syndrome), abnormal repair of DNA 163-9
BV13S2 gene, TCR marker analysis 311-22
BV6S3 gene, TCR marker analysis 311-22
BV6S7 gene, TCR marker analysis 311-22

C ε transcript, stimulated B cells 265-75
C4 (complement factor 4) null alleles, Swedish distribution 435-41
C4A*Q0 homozygous prevalence 435-41
C4B*Q0 homozygous prevalence 435-41
C4Q0: *see* C4 null alleles
canine DLA-A, -B, biochemical definition 199-207
carcinoma, inflammatory, HLA-DR expression 299-310
carcinoma (breast)
  HLA-DQ expression 299-310
  HLA-DR expression 299-310
CD3D gene, TCR marker analysis 311-22
CD4, in vitiligo patients 209-13
CD40L (cell surface molecule) 311-22
CD46 antigen 147-61
cell surface molecules, in EOPA-JCA 311-22
chimpanzee HLA-B, and human B73 a^3 231-40
chromatin structure alteration, by unmethylation 265-75
class I analysis, with mAb B1·23·2 363-70
class I exons 1 & 2 polymorphic motifs 283-7
class I expression
  horse 249-60
  in human B lymphoblatoid cell line 479-83
  see also HLA
class I polymorphism, vitiligo patients 209-13
class II allogenotype markers for human RSA 323-34
class II antigens, CTL induction 425-34
class II polymorphism, vitiligo patients 209-13
class II: *see also* HLA
complement factor 4: *see* C4
computers, double registration of transplant patients 221-3
CTL (cytotoxic T lymphocytes), induction by class II antigens 425-34
Cw6, in vitiligo patients 209-13
cytokine genes, in EOPA-JCA 311-22
cytokine receptor gene (IL5RA), in EOPA-JCA 311-22
cytotoxic T lymphocytes: *see* CTL

digestion protocol, heterozygous DRB1 combination differentiation 371-92
dimorphism, FCγII receptor 397-401
DLA-A (canine), biochemical definition 199-207
DLA-A9, Beagle/Labrador subtypes 199-207
DLA-B (canine), biochemical definition 199-207

DNA
abnormal repair (BS) 163-9
methylation pattern, stimulated B cells 265-75
molecular typing, in IgA-D 403-11
DNA profile: *see* immunoprinting
cDNA library, horse 249-60
cDNA sequences, HLA-B73 231-40
double digestion, for DRB1 heterozygous allele differentiation 371-92

early onset pauciarticular chronic arthritis: *see* EOPA-JCA
ELA-A locus (horse) 249-60
electrophoresis, ambient temperature 467-78
EOPA-JCA (early onset pauciarticular chronic arthritis) 311-22
Epstein-Barr virus, cell immortalization 265-75
exon
ARMS-PCR gene mapping 283-7
HLA-B44 polymorphism 215-20

FCγII receptor 397-401
FcR blocking, by a-chain of TLX system 147-61
FctR blocking antibody production 147-61
fetal loss: *see* abortion, spontaneous
fetus, immunological recognition: *see* abortion, spontaneous
FGF-a, in EOPA-JCA 311-22

gene mapping, using ARMS-PCR 283-7
genes
cytokine, in EOPA-JCA 311-22
TCR analysis 311-22
germline C ε transcript, stimulated B cells 265-75
Gm phenotypes, in mumps meningitis 393-6
gorilla HLA-B, and human B73 a^3 231-40
Graves' disease, and LST-1 polymorphism 277-82

heavy chain
b^2m heterodimerism 479-83
detection, mAb 363-70
isoforms 363-70
isotype switching, by unmethylation 265-75
leader-constant region splicing 241-7
heavy chain genes, 3' splice site deletion 241-7
HLA
A2 haplotype, and TaqI/DQA RFLP 261-4
A19, in vitiligo patients 209-13
A29(19) allele and sHLA-BCw concentration 363-70

HLA (*contd*)
B, gorilla/chimpanzee, and human B73 a3 231-40
B*44
haplotypic associations 215-20
molecular typing 215-20
B*4402, *4403 sequence differences 215-20
B7 antigens 231-40
B7 CREG antigens 231-40
B21, in vitiligo patients 209-13
B22 antigens 231-40
B27 antigens 231-40
B42 antigens 231-40
B67 antigens 231-40
B73
a1a2 domains 231-40
antigenic characteristics 231-40
cDNA sequences 231-40
B73 antigens 231-40
BCw plasmatic molecule 363-70
DP antigens, CTL induction 425-34
DPB1 analysis, Italian MS patients 171-8
DPB1 polymorphism, in IMN 179-86
DQ
in breast carcinoma 299-310
CTL induction 425-34
IDDM protection 443-65
typing, in IgA-D 403-11
DQ9, and TaqI/DQA RFLP 261-4
DQA/TaqI, RFLP 261-4
DQA1
analysis, Italian MS patients 171-8
IDDM association 443-65
matching, PCR-SSCP 467-78
and TaqI/DQA RFLP 261-4
polymorphism, in IMN 179-86
DQA1*0102
decrease, in Greek IMN 179-86
IDDM protection 443-65
DQA1*0301 alleles, Italian MS patients 171-8
DQA1*0501
autoimmune disease 277-82
increase, in IMN 179-86
DQa chain glutamine residue, in Italian MS patients 171-8
DQB*0201, and autoimmune disease 277-82
DQB1
analysis, Italian MS patients 171-8
and IDDM 289-97, 443-65
matching, PCR-SSCP 467-78
polymorphism, in IMN 179-86

HLA (*contd*)
DQB1*0201 increase, in IMN 179-86
DQB1*0301
autoimmune disease 277-82
Italian MS patients 171-8
DQB1*0602, IDDM protection 443-65
DQB1/IgA-D association 403-11
DR
antigen expression, breast tissue 299-310
IDDM protection 443-65
role similarity to -DQ, -DP 425-34
typing, in IgA-D 403-11
DR1/Br, and RSA 323-34
DR2 alleles, Italian MS patients 171-8
DR3, and RSA 323-34
DR4 and IgA-D autoantibody presence 403-11
DR4, in Yoruba Nigerians 187-90
DR4+ subjects, and HLA-DRB1*0401 association with IDDM 289-97
DR9, and TaqI/DQA RFLP 261-4
DR10
homozygous, immunogentic analysis 191-197
and RSA 323-34
DR13 and IgA-D autoantibody presence 403-11
DR15, IDDM association 443-65
DR16 decrease, in Greek IMN 179-86
DR53
and TaqI/DQA RFLP 261-4
in vitiligo patients 209-13
DRB polymorphism, in IMN 179-86
DRB1, high-resolution typing 371-92
DRB1 analysis, Italian MS patients 171-8
DRB1*11(12), in EOPA-JCA 311-22
DRB1*0103, and HLA-DR10 homozygous individuals 191-7
DRB1*0301, in IMN 179-86
DRB1*0401, and IDDM 289-97
DRB1*0901/DRB1*1001 differentiation 371-92
DRB1/IgA-D association 403-11
DRB3*0301, in IMN 179-86
HLA/TLX allele segregation 147-61
HLA markers, in double registration detection 221-3
Hmy 2 CIR transfection 479-83
horse, MHC evolutionary history 249-60
hyperplastic lesion (breast), HLA-DR expression 299-310

I ε region, stimulated B cells 265-75
IDDM (insulin-dependent diabetes mellitus)
DR/DQ protection 443-65
HLA-DRB1*0401 289-97
LST-1 polymorphism 277-82
idiopathic membranous nephropathy: *see* IMN
IFN-a, in EOPA-JCA 311-22
IgA deficiency (IgA-D), DQ, DR typing 403-11
IgA-D, association with autoantibodies 403-11
IgE, high serum levels 265-75
IgE synthesis 265-75
IgM
deficiency in BS 163-9
production damage by UV 163-9
IL (interleukin)
1A, in EOPA-JCA 311-22
2, in EOPA-JCA 311-22
4, and IgE synthesis 265-75
IL5RA (cytokine receptor gene), in EOPA-JCA 311-22
immunoblotting, canine gene products 199-207
immunoprinting, and EOPA-JCA predisposition 311-22
IMN (idiopathic membranous nephropathy), class II polymorphism 179-86
inflammatory infiltrate, breast tumour 299-310
inheritance pattern, human RSA 323-34
insulin-dependent diabetes mellitus: *see* IDDM
interleukin: *see* IL
intron, leader variable region of immunoglobulin heavy chain 241-7
IRF2 chromosomal region, in EOPA-JCA 311-22
isoelectric focusing: *see* 1D-IEF

Km phenotypes, in mumps meningitis 393-6

LCL (lymphoblastoid cell line), human
BS patients 163-9
rat class I expression 479-83
leader-constant region splicing 241-7
LST-1 (leucocyte specific transcript-1) gene, polymorphism 277-82
lymphoblastoid cell line: *see* LCL

mAb
anti-DQ/-DP 425-34
B1-23-2 363-70
W6/32, and class I heavy chain detection 363-70
MCP (membrane cofactor protein) 147-61
melancocytes: *see* vitiligo

membrane cofactor protein: *see* MCP
meningitis, Gm and Km phenotype frequency 393-6
methylation pattern, stimulated B cells 265-75
MHC class I/II *see* class I/II; HLA
MHC evolutionary history, horse 249-60
b2-microglobulin — class I heavy chain heterodimerism 479-83
microsatellite distribution profile, EOPA-JCA 311-22
MLR, suppression 147-61
MS (multiple sclerosis), class II analysis 171-8
m-chains, truncated 241-7
multiplex ARMS-PCR typing for HLA-DRB1 403-11
mumps meningitis 393-6

neoplasm, benign, HLA-DR expression 299-310
nomenclature, WHO committee meeting March 1995 335-60
nomenclature 1995 update
June 361-2
July 423-4
August 485-6
Nomenclature Report (WHO), funding 335-60
null alleles: *see* C4 null alleles

1D-IEF (one-dimensional isoelectric focusing), canine gene products 199-207

PCR (polymerase chain reaction)
ASA (allele-specific amplification), for DQB1 typing 413-22
RFLP, improvement over for DQB1 typing 413-22
SSCP, ambient temperature matching techniques 467-78
SSO, improvement over for DQB1 typing 413-22
SSP/PCR-SSCP matching correlation 467-78
see also ARMS-PCR
plasmatic class I molecule analysis 363-70
population, C4 null allele differential distribution 435-41
pregnancy, TLX alloantibody induction 147-61
promoter sequences, WHO policy 335-60
Pvu II restriction enzyme digestion 277-82

race, and HLA-DR10 homozygocity 191-197
recurrent spontaneous abortion (RSA): *see* abortion, spontaneous
relative predispositional effect (RPE) analysis, IDDM 443-65
responder pattern, FCγII receptor 397-401
restriction endonuclease cleavage, in DRB1 typing 371-92
RFLP (restriction fragment length polymorphism)
HLA-DRB1 high-resolution typing 403-11
LST-1 in IDDM 277-82
TaqI/DQA 261-4
risk markers, RSA 323-34
ms mRNA, deficient transcription in BS 163-9
RSA (recurrent spontaneous abortion): *see* abortion, spontaneous

S μ S ε combinations, stimulated B cells 265-75
sequence database (WHO), funding 335-60
sequence errors, WHO policy 335-60
sequence update: *see* nomenclature
SSCP: *see* PCR-SSCP
surface expressed molecules, class I, horse 249-60
Sweden, IDDM protection by HLA-DR and -DQ 443-65

T cell receptor (TCR), in EOPA-JCA 311-22
T cells, in vitiligo patients 209-13
TAP 1 allele frequency, Yoruba Nigerians 187-90
TAP 2D, in Yoruba Nigerians 187-90
TaqI/DQA, RFLP 261-4
TCRBV6S1 gene, TCR marker analysis 311-22
TCRDVAJ gene, TCR marker analysis 311-22
TEA gene, TCR marker analysis 311-22
TLX antigens 147-61
TLX-B 147-61
TLX/CD46/MCP phenotype mismatching, and alloantibody induction 147-61
TLX/HLA allele segregation 147-61
TNF-a
EOPA-JCA 311-22
microsatellite alleles, in EOPA-JCA 311-22
polymorphism, in EOPA-JCA 311-22
transfection, Hmy 2 CIR cell line 479-83
transfusion, TLX alloantibody induction 147-61

transplantation
  double registration avoidance 221-3
  DQB1 rapid typing 413-22
  TLX alloantibody induction 147-61
tumoral thrombi, HLA-DR expression 299-310
tumour (breast), HLA-DR expression 299-310
tumour necrosis factor: *see* TNF
typing
  DNA molecular, in IgA-D 403-11
  DQB1 by PCR-ASA 413-22
  HLA-DRB1, high-resolution 371-92

ultraviolet (UV) radiation, DNA abnormal repair in BS 163-9

VHDJH complex 241-7
vitiligo, protective/susceptible genes 209-13
vitiligo patients, class I/II polymorphism 209-13

WHO nomenclature committee: *see* nomenclature